Julie A Johnson, Pharm.D.
Dean Emeritus
Department:
Pharmacotherapy & Translational Research
Business Phone:
(352) 273-6309
Business Email:
julie.johnson@ufl.edu
About Julie A Johnson
Julie Johnson is a dean emeritus at the University of Florida. She recently completed a term as Dean of the UF College of Pharmacy, having served in that role from 2013 to 2022. She received her B.S. in Pharmacy from the Ohio State University and her Pharm.D. from the University of Texas at Austin and the UT Health Science Center at San Antonio. She completed a post-doctoral fellowship in cardiovascular pharmacology/ pharmacokinetics at Ohio State.
Dr. Johnson’s research focuses on cardiovascular pharmacogenomics and implementation of precision medicine approaches into clinical practice. She is an internationally recognized leader in clinical pharmacology, pharmacogenomics and genomic medicine, with over 330 peer reviewed original publications and over $50M in research funding as principal investigator. In 2015, 2016, 2017 and 2018 she was named a Clarivate Analytics Highly Cited Researcher, indicating she was in the top 1% most highly cited scientists globally in the discipline in previous decade (pharmacology and toxicology 2015-2017 and across disciplines in 2018).
Under her leadership as dean, the UF College of Pharmacy implemented a new Pharm.D. curriculum, its faculty grew by 90%, the U.S. News & World Report ranking rose from #14 to #5, research funding grew 3.8-fold and research funding rankings rose from the high teens to #3, and it had the highest percentage of under-represented minority students among professional degree programs at UF and the top 40 colleges of pharmacy, with the percentage or URM Pharm.D. students doubling in her time as dean.
Dr. Johnson has had numerous service roles, including with the NIH, FDA, CDC, American Heart Association, American College of Clinical Pharmacy (ACCP) and American Society for Clinical Pharmacology and Therapeutics (ASCPT), for which she served as President in 2016-17. She is currently serving as President-Elect of the Pharmacogenomics Global Research Network, and President of the Academy for Science, Engineering and Medicine – Florida (ASEM-FL). Dr. Johnson has received numerous awards and honors. She was elected to the National Academy of Medicine, and has been the recipient of the Leon I Goldberg Young Investigator Award, Rawls Palmer Progress in Medicine Award and Mentoring Award from the ASCPT, Volwiler Research Achievement Award from the American Association of Colleges of Pharmacy (AACP) (2007), the Therapeutic Frontiers Award, and Paul Parker Medal from ACCP, the ACCP-Pharmacology Distinguished Scientist Award, the Luminary Award from the Precision Medicine World Conference, among others. She has also received teaching awards from both the University of Tennessee and the University of Florida.
Accomplishments
Luminary Award
2021
·
Precision Medicine World Conference
Rawls Palmer Progress in Medicine Award
2021
·
American Society for Clinical Pharmacology and Therapeutics
Elected Fellow
2020
·
American Association for the Advancement of Science
Distinguished Investigator Award
2019
·
American College of Clinical Pharmacology
Paul Parker Medal
2019
·
American College of Clinical Pharmacy
Volwiler Research Achievement Award
2016
·
American Association of Colleges of Pharmacy
Highly Cited Scientist
2015-2018
·
Clarivate Analytics
Distinguished Scientist Award
2015
·
Southeastern Universities Research Associate
Elected Member
2014
·
National Academy of Medicine
Honorary Fellow Award
2014
·
American College of Clinical Pharmacology
Russell Miller Award for Contribution to the Literature
2010
·
American College of Clinical Pharmacy
Fellow
2009
·
American Heart Association; Functional Genomics and Translational Biology Council
Therapeutic Frontiers Award
2009
·
American College of Clinical Pharmacy
Paul Dawson Biotechnology Research Award
2007
·
American Association of Colleges of Pharmacy
Leon I. Goldberg Young Investigator Award
2004
·
American Society for Clinical Pharmacology and Therapeutics
William Oxley Thompson Alumni Award
1997
·
The Ohio State University
Fellow
1996
·
American College of Clinical Pharmacy
Teaching Profile
Courses Taught
2013-2021
PHA7979 Advanced Research
2020
PHA6910 Supervised Research
2013-2025
PHA7980 Research for Doctoral Dissertation
2014-2018,2021-2022
PHA6938 Research Seminar
2016
PHA6971 Research for Master’s Thesis
2015
GMS7794 Neuroscience Seminar
2009-2011,2013
PHA5907 Research in Phar Prac
2013
PHA5933 Select Top Pharmacy
2012-2013
PHA5787 Pharmacotherapy 5
2011-2012
PHA5782 Pharmacotherapy 2
2012
PHA5113 Personalized Medicine
2011-2012
PHA5784 Pharmacotherapy 4
2008,2010-2012,2012
PHA6449 Pharmacogenomics
2011
PHA5113C Thera Mon/Pharmacogen
2009-2010
PHA4907 Probs in Pharm Prac
2010
IDH4917 Undergrad Research
Publications
Academic Articles
2024
Circulating microRNA Biomarkers of Thiazide Response in Hypertension.
Journal of the American Heart Association.
13(4)
[DOI] 10.1161/JAHA.123.032433.
[PMID] 38353215.
2024
CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention.
Journal of the American Heart Association.
13(12)
[DOI] 10.1161/JAHA.123.033791.
[PMID] 38874073.
2024
Effectiveness of Clopidogrel vs Alternative P2Y12 Inhibitors Based on the ABCD-GENE Score.
Journal of the American College of Cardiology.
83(15):1370-1381
[DOI] 10.1016/j.jacc.2024.02.015.
[PMID] 38599713.
2024
Implementing a pragmatic clinical trial to tailor opioids for chronic pain on behalf of the IGNITE ADOPT PGx investigators.
Clinical and translational science.
17(8)
[DOI] 10.1111/cts.70005.
[PMID] 39177194.
2024
Use of CYP2D6 Inhibitors with CYP2D6 Opioids: Association with Emergency Department Visits for Pain.
Clinical pharmacology and therapeutics.
116(4):1005-1012
[DOI] 10.1002/cpt.3314.
[PMID] 38797987.
2023
A Pharmacogenetics-Based Approach to Managing Gastroesophageal Reflux Disease: Current Perspectives and Future Steps.
Pharmacogenomics and personalized medicine.
16:645-664
[DOI] 10.2147/PGPM.S371994.
[PMID] 37383676.
2023
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention.
Clinical pharmacology and therapeutics.
113(3):615-623
[DOI] 10.1002/cpt.2776.
[PMID] 36306392.
2023
Use of a multi-gene pharmacogenetic panel reduces adverse drug effects.
Cell reports. Medicine.
4(5)
[DOI] 10.1016/j.xcrm.2023.101021.
[PMID] 37084734.
2022
A randomized, cross-over trial of metoprolol succinate formulations to evaluate PK and PD end points for therapeutic equivalence.
Clinical and translational science.
15(7):1764-1775
[DOI] 10.1111/cts.13294.
[PMID] 35488487.
2022
Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis.
Frontiers in physiology.
13
[DOI] 10.3389/fphys.2022.909870.
[PMID] 35812313.
2022
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.
Clinical pharmacology and therapeutics.
112(5):959-967
[DOI] 10.1002/cpt.2526.
[PMID] 35034351.
2022
Comparison of Data Normalization Strategies for Array-Based MicroRNA Profiling Experiments and Identification and Validation of Circulating MicroRNAs as Endogenous Controls in Hypertension.
Frontiers in genetics.
13
[DOI] 10.3389/fgene.2022.836636.
[PMID] 35432462.
2022
Contribution of Common Genetic Variants to Risk of Early-Onset Ischemic Stroke.
Neurology.
99(16):e1738-e1754
[DOI] 10.1212/WNL.0000000000201006.
[PMID] 36240095.
2022
CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.
Journal of the American Heart Association.
11(4)
[DOI] 10.1161/JAHA.121.024159.
[PMID] 35156424.
2022
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.
Expert opinion on drug metabolism & toxicology.
18(11):769-785
[DOI] 10.1080/17425255.2022.2160317.
[PMID] 36597259.
2022
Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension.
Contemporary clinical trials.
119
[DOI] 10.1016/j.cct.2022.106813.
[PMID] 35660539.
2022
Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study.
Genes.
13(7)
[DOI] 10.3390/genes13071260.
[PMID] 35886043.
2022
Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation.
Clinical pharmacology and therapeutics.
112(1):146-155
[DOI] 10.1002/cpt.2612.
[PMID] 35429163.
2022
Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators.
Clinical and translational science.
15(10):2479-2492
[DOI] 10.1111/cts.13376.
[PMID] 35899435.
2022
Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients
Metabolites.
12(9)
[DOI] 10.3390/metabo12090783.
[PMID] 36144188.
2022
Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients.
Clinical and translational science.
15(12):2858-2867
[DOI] 10.1111/cts.13396.
[PMID] 36271676.
2022
Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles.
Clinical pharmacology and therapeutics.
111(4):950-955
[DOI] 10.1002/cpt.2549.
[PMID] 35108398.
2022
β1-receptor polymorphisms and junctional ectopic tachycardia in children after cardiac surgery.
Clinical and translational science.
15(3):619-625
[DOI] 10.1111/cts.13178.
[PMID] 34713976.
2021
A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management.
Genetics in medicine : official journal of the American College of Medical Genetics.
23(4):621-628
[DOI] 10.1038/s41436-020-01050-4.
[PMID] 33420349.
2021
Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies.
Clinical pharmacology and therapeutics.
110(3):723-732
[DOI] 10.1002/cpt.2355.
[PMID] 34231218.
2021
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.
Clinical pharmacology and therapeutics.
109(6):1417-1423
[DOI] 10.1002/cpt.2015.
[PMID] 32770672.
2021
Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease.
The pharmacogenomics journal.
21(6):657-663
[DOI] 10.1038/s41397-021-00244-6.
[PMID] 34075203.
2021
Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network.
Genetics in medicine : official journal of the American College of Medical Genetics.
23(7):1185-1191
[DOI] 10.1038/s41436-021-01118-9.
[PMID] 33782552.
2021
Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality.
European heart journal.
42(18):1742-1756
[DOI] 10.1093/eurheartj/ehab107.
[PMID] 33748830.
2021
How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial.
Clinical pharmacology and therapeutics.
110(3):677-687
[DOI] 10.1002/cpt.2354.
[PMID] 34231197.
2021
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Clinical pharmacology and therapeutics.
109(3):705-715
[DOI] 10.1002/cpt.2039.
[PMID] 32897581.
2021
Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients.
Metabolites.
11(9)
[DOI] 10.3390/metabo11090645.
[PMID] 34564461.
2021
Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing.
Genetics in medicine : official journal of the American College of Medical Genetics.
23(12):2335-2341
[DOI] 10.1038/s41436-021-01269-9.
[PMID] 34282303.
2021
Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone.
The American journal of medicine.
134(7):918-925.e2
[DOI] 10.1016/j.amjmed.2020.12.015.
[PMID] 33434556.
2021
Racial disparities in survival outcomes among breast cancer patients by molecular subtypes.
Breast cancer research and treatment.
185(3):841-849
[DOI] 10.1007/s10549-020-05984-w.
[PMID] 33111220.
2021
Strategies to Integrate Genomic Medicine into Clinical Care: Evidence from the IGNITE Network.
Journal of personalized medicine.
11(7)
[DOI] 10.3390/jpm11070647.
[PMID] 34357114.
2021
Tribute to Professor Hartmut Derendorf – 1953 to 2020: Driving force in Clinical Pharmacology and Mentor Extraordinaire.
Clinical pharmacology and therapeutics.
109(4):805-809
[DOI] 10.1002/cpt.2193.
[PMID] 33667324.
2020
A Scoping Review of the Evidence Behind Cytochrome P450 2D6 Isoenzyme Inhibitor Classifications.
Clinical pharmacology and therapeutics.
108(1):116-125
[DOI] 10.1002/cpt.1768.
[PMID] 31910286.
2020
Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data.
Circulation.
142(6):546-555
[DOI] 10.1161/CIRCULATIONAHA.119.045526.
[PMID] 32654539.
2020
Blending Traditional Vocational Services and Individualized Placement and Support for Formerly Incarcerated Veterans.
Psychiatric services (Washington, D.C.).
71(8):816-823
[DOI] 10.1176/appi.ps.201900421.
[PMID] 32393158.
2020
Clinical Pharmacology Education – The Decade Ahead.
Clinical pharmacology and therapeutics.
107(1):37-39
[DOI] 10.1002/cpt.1652.
[PMID] 31709518.
2020
Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention.
Clinical and translational science.
13(3):473-481
[DOI] 10.1111/cts.12729.
[PMID] 31758664.
2020
Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting.
American journal of hypertension.
33(4):316-324
[DOI] 10.1093/ajh/hpz196.
[PMID] 31853537.
2020
Correction: Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.
Genetics in medicine : official journal of the American College of Medical Genetics.
22(11)
[DOI] 10.1038/s41436-020-0931-1.
[PMID] 32747766.
2020
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
The pharmacogenomics journal.
20(5):724-735
[DOI] 10.1038/s41397-020-0162-5.
[PMID] 32042096.
2020
Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult Clinic.
Journal of clinical medicine.
9(7)
[DOI] 10.3390/jcm9072274.
[PMID] 32708920.
2020
Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.
Genetics in medicine : official journal of the American College of Medical Genetics.
22(11):1898-1902
[DOI] 10.1038/s41436-020-0894-2.
[PMID] 32678355.
2020
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
CPT: pharmacometrics & systems pharmacology.
9(12):678-685
[DOI] 10.1002/psp4.12563.
[PMID] 33067866.
2020
How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial.
Clinical pharmacology and therapeutics.
108(3):557-565
[DOI] 10.1002/cpt.1912.
[PMID] 32460360.
2020
Pharmacogenetic factors affecting β-blocker metabolism and response.
Expert opinion on drug metabolism & toxicology.
16(10):953-964
[DOI] 10.1080/17425255.2020.1803279.
[PMID] 32726152.
2020
Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence.
American journal of hypertension.
33(2)
[DOI] 10.1093/ajh/hpz168.
[PMID] 31891170.
2020
Sorting nexin 1 loss results in increased oxidative stress and hypertension.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
34(6):7941-7957
[DOI] 10.1096/fj.201902448R.
[PMID] 32293069.
2020
The Patient-Centered Future of Clinical Pharmacology.
Clinical pharmacology and therapeutics.
107(1):72-75
[DOI] 10.1002/cpt.1681.
[PMID] 31751490.
2019
A case for genotype-guided pain management.
Pharmacogenomics.
20(10):705-708
[DOI] 10.2217/pgs-2019-0068.
[PMID] 31368851.
2019
Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease.
Journal of clinical hypertension (Greenwich, Conn.).
21(1):91-101
[DOI] 10.1111/jch.13429.
[PMID] 30427124.
2019
Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events.
Circulation. Genomic and precision medicine.
12(4)
[DOI] 10.1161/CIRCGEN.119.002471.
[PMID] 30897348.
2019
Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings.
Genetics in medicine : official journal of the American College of Medical Genetics.
21(10):2264-2274
[DOI] 10.1038/s41436-019-0500-7.
[PMID] 30926959.
2019
CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.
Genetics in medicine : official journal of the American College of Medical Genetics.
21(8):1842-1850
[DOI] 10.1038/s41436-018-0431-8.
[PMID] 30670877.
2019
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.
Clinical pharmacology and therapeutics.
105(6):1477-1491
[DOI] 10.1002/cpt.1323.
[PMID] 30506689.
2019
Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
131:93-98
[DOI] 10.1016/j.ejps.2019.02.013.
[PMID] 30753892.
2019
Essential Characteristics of Pharmacogenomics Study Publications.
Clinical pharmacology and therapeutics.
105(1):86-91
[DOI] 10.1002/cpt.1279.
[PMID] 30406943.
2019
Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals.
Hypertension (Dallas, Tex. : 1979).
74(3):614-622
[DOI] 10.1161/HYPERTENSIONAHA.118.12177.
[PMID] 31327267.
2019
Genetic and lifestyle risk factors for MRI-defined brain infarcts in a population-based setting.
Neurology.
92(5):e486-e503
[DOI] 10.1212/WNL.0000000000006851.
[PMID] 30651383.
2019
Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response.
Scientific reports.
9(1)
[DOI] 10.1038/s41598-019-53345-5.
[PMID] 31754133.
2019
Genome-wide association analysis of common genetic variants of resistant hypertension.
The pharmacogenomics journal.
19(3):295-304
[DOI] 10.1038/s41397-018-0049-x.
[PMID] 30237584.
2019
Genome-Wide Meta-Analysis of Blood Pressure Response to β1-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies).
Journal of the American Heart Association.
8(16)
[DOI] 10.1161/JAHA.119.013115.
[PMID] 31423876.
2019
Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta-Blockers in European Americans.
Clinical and translational science.
12(5):497-504
[DOI] 10.1111/cts.12643.
[PMID] 31033190.
2019
Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers.
PloS one.
14(9)
[DOI] 10.1371/journal.pone.0221957.
[PMID] 31532792.
2019
Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing.
Genetics in medicine : official journal of the American College of Medical Genetics.
21(10):2255-2263
[DOI] 10.1038/s41436-019-0484-3.
[PMID] 30894703.
2019
Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial.
Clinical and translational science.
12(2):172-179
[DOI] 10.1111/cts.12589.
[PMID] 30341969.
2019
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
American journal of hypertension.
32(7):668-675
[DOI] 10.1093/ajh/hpz022.
[PMID] 30753254.
2019
Publisher Correction: Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes.
Nature genetics.
51(7):1192-1193
[DOI] 10.1038/s41588-019-0449-0.
[PMID] 31160810.
2019
Qualitative study of system-level factors related to genomic implementation.
Genetics in medicine : official journal of the American College of Medical Genetics.
21(7):1534-1540
[DOI] 10.1038/s41436-018-0378-9.
[PMID] 30467402.
2019
Subsequent Event Risk in Individuals With Established Coronary Heart Disease.
Circulation. Genomic and precision medicine.
12(4)
[DOI] 10.1161/CIRCGEN.119.002470.
[PMID] 30896328.
2019
β2 -Adrenergic Receptor Gene Affects the Heart Rate Response of β-Blockers: Evidence From 3 Clinical Studies.
Journal of clinical pharmacology.
59(11):1462-1470
[DOI] 10.1002/jcph.1443.
[PMID] 31090079.
2018
Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies.
BMC medical genomics.
11(1)
[DOI] 10.1186/s12920-018-0370-x.
[PMID] 29925376.
2018
Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
Journal of translational medicine.
16(1)
[DOI] 10.1186/s12967-018-1469-8.
[PMID] 29642909.
2018
Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine.
Public health genomics.
21(5-6):217-227
[DOI] 10.1159/000500725.
[PMID] 31189173.
2018
Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).
Circulation. Genomic and precision medicine.
11(4)
[DOI] 10.1161/CIRCGEN.117.001854.
[PMID] 29650764.
2018
Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients.
Journal of the American Heart Association.
7(6)
[DOI] 10.1161/JAHA.117.007339.
[PMID] 29523524.
2018
Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β-Blockers.
Journal of the American Heart Association.
7(5)
[DOI] 10.1161/JAHA.117.006463.
[PMID] 29478026.
2018
Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned.
Clinical and translational science.
11(2):175-181
[DOI] 10.1111/cts.12533.
[PMID] 29351371.
2018
Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes.
Nature genetics.
50(4):524-537
[DOI] 10.1038/s41588-018-0058-3.
[PMID] 29531354.
2018
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions.
11(2):181-191
[DOI] 10.1016/j.jcin.2017.07.022.
[PMID] 29102571.
2018
Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.
Clinical pharmacology and therapeutics.
104(4):664-674
[DOI] 10.1002/cpt.1006.
[PMID] 29280137.
2018
Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.
Expert opinion on drug metabolism & toxicology.
14(4):447-460
[DOI] 10.1080/17425255.2018.1461835.
[PMID] 29620484.
2018
Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects.
Clinical pharmacology and therapeutics.
103(5):778-786
[DOI] 10.1002/cpt.1048.
[PMID] 29460415.
2018
Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide.
Pharmacogenetics and genomics.
28(11):251-255
[DOI] 10.1097/FPC.0000000000000353.
[PMID] 30289819.
2018
Whole Transcriptome Profiling: An RNA-Seq Primer and Implications for Pharmacogenomics Research.
Clinical and translational science.
11(2):153-161
[DOI] 10.1111/cts.12511.
[PMID] 28945944.
2017
Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension.
Journal of clinical hypertension (Greenwich, Conn.).
19(12):1301-1308
[DOI] 10.1111/jch.13094.
[PMID] 28940643.
2017
Comparison of Whole-Genome Sequencing Methods for Analysis of Three Methicillin-Resistant Staphylococcus aureus Outbreaks.
Journal of clinical microbiology.
55(6):1946-1953
[DOI] 10.1128/JCM.00029-17.
[PMID] 28404677.
2017
Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms.
Nature genetics.
49(7):1113-1119
[DOI] 10.1038/ng.3874.
[PMID] 28530674.
2017
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.
Journal of the American Heart Association.
6(11)
[DOI] 10.1161/JAHA.117.006522.
[PMID] 29097388.
2017
Genetic variation at 16q24.2 is associated with small vessel stroke.
Annals of neurology.
81(3):383-394
[DOI] 10.1002/ana.24840.
[PMID] 27997041.
2017
Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide.
Hypertension (Dallas, Tex. : 1979).
69(1):51-59
[PMID] 27802415.
2017
Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response.
Circulation. Cardiovascular genetics.
10(1)
[DOI] 10.1161/CIRCGENETICS.116.001404.
[PMID] 28115488.
2017
Genome-wide study of resistant hypertension identified from electronic health records.
PloS one.
12(2)
[DOI] 10.1371/journal.pone.0171745.
[PMID] 28222112.
2017
Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Pharmacogenetics and genomics.
27(5):190-196
[DOI] 10.1097/FPC.0000000000000277.
[PMID] 28306618.
2017
Institutional profile: University of Florida Health Personalized Medicine Program.
Pharmacogenomics.
18(5):421-426
[DOI] 10.2217/pgs-2017-0028.
[PMID] 28346068.
2017
Patient and caregiver characteristics related to completion of advance directives in terminally ill patients.
Palliative & supportive care.
15(1):12-19
[DOI] 10.1017/S147895151600016X.
[PMID] 27237410.
2017
Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes).
Stroke.
48(5):1337-1343
[DOI] 10.1161/STROKEAHA.116.015936.
[PMID] 28351962.
2017
Relations Between Lipoprotein(A) Concentrations, Lpa Genetic Variants, and the Risk of Mortality in Patients With Established Coronary Heart Disease: a Molecular and Genetic Association Study
Lancet Diabetes and Endocrinology.
5(7):534-543
[DOI] 10.1016/S2213-8587(17)30096-7.
[PMID] 28566218.
2017
Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics.
Journal of the American Heart Association.
7(1)
[DOI] 10.1161/JAHA.117.006656.
[PMID] 29288159.
2017
The Trial of Ascertaining Individual Preferences for Loved Ones’ Role in End-of-Life Decisions (TAILORED) Study: A Randomized Controlled Trial to Improve Surrogate Decision Making.
Journal of pain and symptom management.
54(4):455-465
[DOI] 10.1016/j.jpainsymman.2017.07.004.
[PMID] 28712987.
2017
Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics.
Scientific reports.
7(1)
[DOI] 10.1038/s41598-017-16343-z.
[PMID] 29167564.
2016
A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration.
Hypertension (Dallas, Tex. : 1979).
68(3):621-9
[DOI] 10.1161/HYPERTENSIONAHA.116.07328.
[PMID] 27381900.
2016
CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril.
European journal of clinical pharmacology.
72(6):681-7
[DOI] 10.1007/s00228-016-2029-x.
[PMID] 26915813.
2016
Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension.
American journal of hypertension.
29(10):1186-94
[DOI] 10.1093/ajh/hpw067.
[PMID] 27365079.
2016
CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
Journal of neurosurgery.
124(6):1746-51
[DOI] 10.3171/2015.6.JNS15795.
[PMID] 26587656.
2016
Effects of Using Personal Genotype Data on Student Learning and Attitudes in a Pharmacogenomics Course.
American journal of pharmaceutical education.
80(7)
[PMID] 27756930.
2016
Genetic and Non-Genetic Factors Affecting Clopidogrel Efficacy in Egyptian Population
.
9(1):23-28
2016
Hypertension Pharmacogenomics: In Search of Personalized Treatment Approaches
.
12:10-22
2016
Hypertension pharmacogenomics: in search of personalized treatment approaches.
Nature reviews. Nephrology.
12(2):110-22
[DOI] 10.1038/nrneph.2015.176.
[PMID] 26592190.
2016
Identification of Additional Risk Loci for Stroke and Small Vessel Disease: A Meta-Analysis of Genome Wide Association Studies
Lancet Neurology.
2016
Identification of Suitable Endogenous Normalizers for qRT-PCR Analysis of Plasma microRNA Expression in Essential Hypertension.
Molecular biotechnology.
58(3):179-87
[DOI] 10.1007/s12033-015-9912-z.
[PMID] 26798072.
2016
Impact of GGCX, STX1B, and FPGS Polymorphisms on Warfarin Dose Requirements in European Americans and Egyptians
.
9(1):36-42
2016
Implementation of inpatient models of pharmacogenetics programs.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
73(23):1944-1954
[PMID] 27864202.
2016
Mechanisms and pharmacogenetic signals underlying thiazide diuretics blood pressure response.
Current opinion in pharmacology.
27:31-7
[DOI] 10.1016/j.coph.2016.01.005.
[PMID] 26874237.
2016
Melatonin Pathway and Atenolol-Related Glucose Dysregulation- Is There a Correlation?
.
9(2):114-122
2016
Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach.
Metabolomics : Official journal of the Metabolomic Society.
12(8)
[DOI] 10.1007/s11306-016-1076-8.
[PMID] 28217400.
2016
Pharmacists should jump onto the clinical pharmacogenetics train.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
73(23):2013-2016
[PMID] 27864209.
2016
Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to β-Blockers in Hypertensive African Americans.
Hypertension (Dallas, Tex. : 1979).
67(3):556-63
[DOI] 10.1161/HYPERTENSIONAHA.115.06345.
[PMID] 26729753.
2016
Population-Specific Single Nucleotide Polymorphism Confers Increased Risk of Venous Thromboembolism in African Americans
.
2016
Population-specific single-nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans.
Molecular genetics & genomic medicine.
4(5):513-20
[DOI] 10.1002/mgg3.226.
[PMID] 27652279.
2016
Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol.
Metabolomics : Official journal of the Metabolomic Society.
12(10)
[DOI] 10.1007/s11306-016-1098-2.
[PMID] 28217401.
2016
The IGNITE network: a model for genomic medicine implementation and research.
BMC medical genomics.
9
[DOI] 10.1186/s12920-015-0162-5.
[PMID] 26729011.
2015
A Genome-Wide Association Study of Ischemic Stroke and its Subtypes Identifies a Novel Locus Near TSPAN2 for Stroke Related to Atherosclerosis
Lancet Neurology.
2015
A novel simple method for determining CYP2D6 gene copy number and identifying allele(s) with duplication/multiplication.
PloS one.
10(1)
[DOI] 10.1371/journal.pone.0113808.
[PMID] 25625348.
2015
Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes
.
4(11):669-679
2015
Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients.
Metabolic syndrome and related disorders.
13(5):195-202
[DOI] 10.1089/met.2014.0132.
[PMID] 25664967.
2015
CYP2C19 Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study
.
4(6)
2015
CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Journal of the American Heart Association.
4(6)
[DOI] 10.1161/JAHA.114.001652.
[PMID] 26019129.
2015
Floppy mitral valve/mitral valve prolapse syndrome: Beta-adrenergic receptor polymorphism may contribute to the pathogenesis of symptoms.
Journal of cardiology.
65(5):434-8
[DOI] 10.1016/j.jjcc.2014.07.020.
[PMID] 25172623.
2015
Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association.
Circulation.
131(19):1715-36
[DOI] 10.1161/CIR.0000000000000211.
[PMID] 25882488.
2015
Genome-wide association study of warfarin maintenance dose in a Brazilian sample.
Pharmacogenomics.
16(11):1253-63
[DOI] 10.2217/PGS.15.73.
[PMID] 26265036.
2015
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies.
Journal of the National Cancer Institute.
107(2)
[DOI] 10.1093/jnci/dju437.
[PMID] 25638249.
2015
Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.
Journal of the American Heart Association.
4(1)
[DOI] 10.1161/JAHA.115.001778.
[PMID] 25622599.
2015
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.
Journal of hypertension.
33(11):2278-85
[DOI] 10.1097/HJH.0000000000000714.
[PMID] 26425837.
2015
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives.
Journal of hypertension.
33(6):1301-9
[DOI] 10.1097/HJH.0000000000000541.
[PMID] 25695618.
2015
Transethnic Meta Analyses Suggests Genetic Variation in the HEME Pathway Influences Potassium Response in Patients Treated with Hydrochlorothiazide
.
15(2):153-157
2015
Vascular Smooth Muscle Cells From Hypertensive Patient-Derived Induced Pluripotent Stem Cells to Advance Hypertension Pharmacogenomics.
Stem cells translational medicine.
4(12):1380-90
[DOI] 10.5966/sctm.2015-0126.
[PMID] 26494780.
2015
Warfarin pharmacogenetics.
Trends in cardiovascular medicine.
25(1):33-41
[DOI] 10.1016/j.tcm.2014.09.001.
[PMID] 25282448.
2014
A Novel Simple Method for Determining Cyp2D6 Gene Copy Number and Identifying Allele(S) With Duplication/Multiplication.
Clinical Pharmacology & Therapeutics.
95(1)
2014
Alteration in fasting glucose after prolonged treatment with a thiazide diuretic.
Diabetes research and clinical practice.
104(3):363-9
[DOI] 10.1016/j.diabres.2014.04.004.
[PMID] 24794890.
2014
Baseline Predictors of Central Aortic Blood Pressure: a Pear Substudy
Journal of the American Society of Hypertension.
8(3):152-158
[DOI] 10.1016/j.jash.2013.12.008.
[PMID] 24629400.
2014
Clinical pharmacogenetics implementation: approaches, successes, and challenges.
American journal of medical genetics. Part C, Seminars in medical genetics.
166C(1):56-67
[DOI] 10.1002/ajmg.c.31390.
[PMID] 24616371.
2014
CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
Pharmacotherapy.
34(7):703-18
[DOI] 10.1002/phar.1400.
[PMID] 24510446.
2014
Emerging roles for pharmacists in clinical implementation of pharmacogenomics.
Pharmacotherapy.
34(10):1102-12
[DOI] 10.1002/phar.1481.
[PMID] 25220280.
2014
Gene-centric meta-analyses for central adiposity traits in up to 57 412 individuals of European descent confirm known loci and reveal several novel associations.
Human molecular genetics.
23(9):2498-510
[DOI] 10.1093/hmg/ddt626.
[PMID] 24345515.
2014
Gene-Centric Meta-Analysis in 87,736 Individuals of European Ancestry Identifies Multiple Blood Pressure Related Loci
.
94(3):349-360
2014
Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci.
American journal of human genetics.
94(3):349-60
[DOI] 10.1016/j.ajhg.2013.12.016.
[PMID] 24560520.
2014
Genetic influence on exercise-induced changes in physical function among mobility-limited older adults.
Physiological genomics.
46(5):149-58
[DOI] 10.1152/physiolgenomics.00169.2013.
[PMID] 24423970.
2014
Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.
Blood.
124(14):2298-305
[DOI] 10.1182/blood-2014-04-568436.
[PMID] 25079360.
2014
Genome-Wide Association Analyses Suggest Nell1 Influences Adverse Metabolic Response to HCTZ in African-Americans
.
14(1):35-40
2014
Hydrochlorothiazide-Induced Hyperuricemia in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study
Journal of internal medicine (Online).
276:486-497
2014
Impact of CYP2D6 Polymorphisms on Clinical Efficacy and Tolerability of Metoprolol Tartrate
Clinical Pharmacology & Therapeutics.
96(2):175-181
2014
Is diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose?
Circulation. Cardiovascular genetics.
7(2):199-205
[DOI] 10.1161/CIRCGENETICS.113.000421.
[PMID] 24627569.
2014
Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension.
Journal of the American Heart Association.
3(6)
[DOI] 10.1161/JAHA.114.001398.
[PMID] 25385345.
2014
Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension.
American journal of hypertension.
27(4):546-54
[DOI] 10.1093/ajh/hpt124.
[PMID] 23886594.
2014
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.
Pharmacotherapy.
34(11):1132-40
[DOI] 10.1002/phar.1483.
[PMID] 25202885.
2014
PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.
Pharmacotherapy.
34(2):123-30
[DOI] 10.1002/phar.1355.
[PMID] 24122840.
2014
The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping.
Pharmacogenetics and genomics.
24(8):381-6
[DOI] 10.1097/FPC.0000000000000068.
[PMID] 24945780.
2013
A pharmacogenetic versus a clinical algorithm for warfarin dosing.
The New England journal of medicine.
369(24):2283-93
[DOI] 10.1056/NEJMoa1310669.
[PMID] 24251361.
2013
Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis.
Journal of the American College of Cardiology.
61(9):957-70
[DOI] 10.1016/j.jacc.2012.10.051.
[PMID] 23352782.
2013
Association of Chromosome 12 Locus With Antihypertensive Response To Hydrochlorothiazide May Involve Differential Yeats4 Expression
Pharmacogenomics Journal.
13(3):257-263
[DOI] 10.1038/tpj.2012.4.
[PMID] 22350108.
2013
Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment.
The pharmacogenomics journal.
13(5):430-6
[DOI] 10.1038/tpj.2012.34.
[PMID] 22907731.
2013
Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics.
Journal of hypertension.
31(4):698-704
[DOI] 10.1097/HJH.0b013e32835e2a71.
[PMID] 23353631.
2013
Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
PloS one.
8(10)
[DOI] 10.1371/journal.pone.0076984.
[PMID] 24116192.
2013
Beta-Adrenergic Receptor Polymorphisms: A Basis for Pharmacogenetics
World Journal of Cardiovascular Diseases.
3:406-411
2013
Clinical implementation of pharmacogenetics: more than one gene at a time.
Clinical pharmacology and therapeutics.
93(5):384-5
[DOI] 10.1038/clpt.2013.7.
[PMID] 23598455.
2013
Clinical Pharmacogenetics Implementation Consortium (CIPIC) Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Clinical Pharmacology & Therapeutics.
94:317-323
2013
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?
Current opinion in cardiology.
28(3):305-14
[DOI] 10.1097/HCO.0b013e32835f0bbc.
[PMID] 23478884.
2013
Development of a Novel Pgy2 Pharmacogenomics and Drug Information Residency in a Personalized Medicine Program
Pharmacotherapy.
33
2013
Expression Quantitative Trait Loci Analysis of Stable Warfarin Dose Identifies Novel Associations: Finding Signal Within the Noise
Clinical Pharmacology & Therapeutics.
93
2013
Gene-Centric Meta-Analyses of 108,912 Individuals Confirm Known Body Mass Index Loci and Reveal Three Novel Signals
Human Molecular Genetics.
22:184-201
2013
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
Lancet (London, England).
382(9894):790-6
[DOI] 10.1016/S0140-6736(13)60681-9.
[PMID] 23755828.
2013
Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes.
Circulation. Cardiovascular genetics.
6(2):184-92
[DOI] 10.1161/CIRCGENETICS.111.964627.
[PMID] 23392654.
2013
Genetics and genomics for the prevention and treatment of cardiovascular disease: update: a scientific statement from the American Heart Association.
Circulation.
128(25):2813-51
[DOI] 10.1161/01.cir.0000437913.98912.1d.
[PMID] 24297835.
2013
Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide.
Hypertension (Dallas, Tex. : 1979).
62(2):391-7
[DOI] 10.1161/HYPERTENSIONAHA.111.00436.
[PMID] 23753411.
2013
Impact of genetic polymorphisms of SLC2A2, SLC2A5, and KHK on metabolic phenotypes in hypertensive individuals.
PloS one.
8(1)
[DOI] 10.1371/journal.pone.0052062.
[PMID] 23341889.
2013
Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes.
Pharmacogenetics and genomics.
23(12):697-705
[DOI] 10.1097/FPC.0000000000000012.
[PMID] 24128935.
2013
Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics.
Pharmacogenomics.
14(7):723-6
[DOI] 10.2217/pgs.13.59.
[PMID] 23651020.
2013
Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort.
Journal of translational medicine.
11
[DOI] 10.1186/1479-5876-11-12.
[PMID] 23302499.
2013
Loci influencing blood pressure identified using a cardiovascular gene-centric array.
Human molecular genetics.
22(8):1663-78
[DOI] 10.1093/hmg/dds555.
[PMID] 23303523.
2013
Pathway analysis of genome-wide data improves warfarin dose prediction.
BMC genomics.
14 Suppl 3(Suppl 3)
[DOI] 10.1186/1471-2164-14-S3-S11.
[PMID] 23819817.
2013
Pharmacogenetics and cardiovascular disease–implications for personalized medicine.
Pharmacological reviews.
65(3):987-1009
[DOI] 10.1124/pr.112.007252.
[PMID] 23686351.
2013
Pharmacogenetics in clinical practice: how far have we come and where are we going?
Pharmacogenomics.
14(7):835-43
[DOI] 10.2217/pgs.13.52.
[PMID] 23651030.
2013
Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes.
Hypertension (Dallas, Tex. : 1979).
62(1):48-54
[DOI] 10.1161/HYPERTENSIONAHA.111.00823.
[PMID] 23690342.
2013
Pharmacometabolomics reveals racial differences in response to atenolol treatment.
PloS one.
8(3)
[DOI] 10.1371/journal.pone.0057639.
[PMID] 23536766.
2013
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.
American heart journal.
166(3):435-41
[DOI] 10.1016/j.ahj.2013.04.009.
[PMID] 24016491.
2013
Stroke Genetics Network (SiGN) study: design and rationale for a genome-wide association study of ischemic stroke subtypes.
Stroke.
44(10):2694-702
[DOI] 10.1161/STROKEAHA.113.001857.
[PMID] 24021684.
2013
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.
Clinical pharmacology and therapeutics.
94(2):207-10
[DOI] 10.1038/clpt.2013.59.
[PMID] 23588301.
2013
VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians.
Thrombosis and haemostasis.
109(6):1045-50
[DOI] 10.1160/TH12-10-0789.
[PMID] 23571513.
2012
Academia at the crossroads: education and training in pharmacogenomics.
Personalized medicine.
9(5):497-506
[DOI] 10.2217/pme.12.54.
[PMID] 29768769.
2012
Advancing management of hypertension through pharmacogenomics.
Annals of medicine.
44 Suppl 1(0 1):S17-22
[DOI] 10.3109/07853890.2011.653399.
[PMID] 22713143.
2012
Alpha Adducin-1 (Add1)Singlenucleotide Polymorphism (Snp) Associated With New Onset Diabetes Risk With Hydrochlorothiazide (Hctz) Therapy in the International Verapamil Sr Trandolapril Genetic Substudy (Invest-Genes)
Clinical Pharmacology & Therapeutics.
91
2012
Antihypertensive Medication Exposure and Adverse Glycemic Effects: An Evaluation of Fasting and Stimulated Glucose
Clinical Pharmacology & Therapeutics.
91
2012
Association of Fto With Hydrochlorothiazide (Hctz)-Induced Elevation in Uric Acid (Ua) in African American (Aa) Hypertensives in the Pharmacogenomic Evaluation of Antihypertensive Response (Pear) Study.
Clinical Pharmacology & Therapeutics.
91:S59-S60
2012
Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol.
American journal of hypertension.
25(3):359-65
[DOI] 10.1038/ajh.2011.215.
[PMID] 22089105.
2012
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk.
PloS one.
7(3)
[DOI] 10.1371/journal.pone.0031930.
[PMID] 22403620.
2012
Clinical Predictors of Dysglycemic Effects Associated With Use of Beta Blockers and Thiazide Diuretics
Clinical Pharmacology & Therapeutics.
91:S24-S25
2012
Clopidogrel: a Case for Indication-Specific Pharmacogenetics
Clinical Pharmacology & Therapeutics.
91(5):774-776
[DOI] 10.1038/clpt.2012.21.
[PMID] 22513313.
2012
Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy.
BMC medical research methodology.
12
[DOI] 10.1186/1471-2288-12-119.
[PMID] 22866767.
2012
CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers.
Drug metabolism and disposition: the biological fate of chemicals.
40(5):884-91
[DOI] 10.1124/dmd.111.044255.
[PMID] 22289258.
2012
Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide.
Journal of translational medicine.
10
[DOI] 10.1186/1479-5876-10-56.
[PMID] 22440088.
2012
Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects.
Metabolism: clinical and experimental.
61(5):641-51
[DOI] 10.1016/j.metabol.2011.09.013.
[PMID] 22152650.
2012
Evaluating the genomic and sequence integrity of human ES cell lines; comparison to normal genomes.
Stem cell research.
8(2):154-64
[DOI] 10.1016/j.scr.2011.10.001.
[PMID] 22265736.
2012
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
Hypertension (Dallas, Tex. : 1979).
60(4):957-64
[DOI] 10.1161/HYPERTENSIONAHA.112.198721.
[PMID] 22949529.
2012
Genetics and cardiovascular disease: a policy statement from the American Heart Association.
Circulation.
126(1):142-57
[DOI] 10.1161/CIR.0b013e31825b07f8.
[PMID] 22645291.
2012
Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate.
Journal of clinical pharmacology.
52(6):837-49
[DOI] 10.1177/0091270011405664.
[PMID] 21642471.
2012
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study.
Circulation. Cardiovascular genetics.
5(6):686-91
[DOI] 10.1161/CIRCGENETICS.112.964080.
[PMID] 23087401.
2012
Hypertension Susceptibility Loci Associated With Blood Pressure Response To Antihypertensives- Results From the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study.
Clinical Pharmacology & Therapeutics.
91
2012
Impact of the Cyp4F2 P.V433M Polymorphism On Coumarin Dose Requirement: Systematic Review and Meta-Analysis
Clinical Pharmacology & Therapeutics.
92(6):746-756
[DOI] 10.1038/clpt.2012.184.
[PMID] 23132553.
2012
Implementing Personalized Medicine: Development of a Cost-Effective Customized Pharmacogenetics Genotyping Array
Clinical Pharmacology & Therapeutics.
92(4):437-439
[DOI] 10.1038/clpt.2012.125.
[PMID] 22910441.
2012
Large-Scale Gene-Centric Meta-Analysis Across 32 Studies Identifies Multiple Lipid Loci
.
91:823-838
2012
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
American journal of human genetics.
91(5):823-38
[DOI] 10.1016/j.ajhg.2012.08.032.
[PMID] 23063622.
2012
Large-Scale Gene-Centric Meta-Analysis Across 39 Studies Identifies Type 2 Diabetes Loci
.
90(3):410-425
2012
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci.
American journal of human genetics.
90(3):410-25
[DOI] 10.1016/j.ajhg.2011.12.022.
[PMID] 22325160.
2012
Non-Synonymous Snps in Sele, Selp, and Siglec12 Associate With Cardiovascular (Cv) Outcomes in the International Verapamil Sr-Trandol-April Study Genetic Substudy (Invest-Genes)
Clinical Pharmacology & Therapeutics.
91:S20-S21
2012
Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response.
Journal of translational medicine.
10
[DOI] 10.1186/1479-5876-10-47.
[PMID] 22413836.
2012
Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension.
Kidney & blood pressure research.
35(6):477-82
[DOI] 10.1159/000337370.
[PMID] 22688828.
2012
Warfarin pharmacogenetics: a rising tide for its clinical value.
Circulation.
125(16):1964-6
[DOI] 10.1161/CIRCULATIONAHA.112.100628.
[PMID] 22431866.
2011
A novel application of pattern recognition for accurate SNP and indel discovery from high-throughput data: targeted resequencing of the glucocorticoid receptor co-chaperone FKBP5 in a Caucasian population.
Molecular genetics and metabolism.
104(4):457-69
[DOI] 10.1016/j.ymgme.2011.08.019.
[PMID] 21917492.
2011
Cardiovascular Pharmacogenomics of Adrenergic Receptor Signaling: Clinical Implications and Future Directions
Clinical Pharmacology & Therapeutics.
89(3):366-378
[DOI] 10.1038/clpt.2010.315.
[PMID] 21289619.
2011
Cardiovascular pharmacogenomics.
Circulation research.
109(7):807-20
[DOI] 10.1161/CIRCRESAHA.110.230995.
[PMID] 21921273.
2011
Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study).
Journal of clinical hypertension (Greenwich, Conn.).
13(12):917-24
[DOI] 10.1111/j.1751-7176.2011.00549.x.
[PMID] 22142351.
2011
Chromosome 9p21 haplotypes and prognosis in white and black patients with coronary artery disease.
Circulation. Cardiovascular genetics.
4(2):169-78
[DOI] 10.1161/CIRCGENETICS.110.959296.
[PMID] 21372283.
2011
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
Clinical Pharmacology & Therapeutics.
90:625-629
2011
Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.
Pharmacotherapy.
31(10):942-50
[DOI] 10.1592/phco.31.10.942.
[PMID] 21950641.
2011
Effects of High Fructose Corn Syrup and Sucrose on the Pharmacokinetics of Fructose and Acute Metabolic and Hemodynamic Responses in Healthy Subjects
.
61:641-651
2011
Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
Pharmacogenetics and genomics.
21(3):130-5
[DOI] 10.1097/FPC.0b013e3283436b86.
[PMID] 21228733.
2011
Genetic warfarin dosing: tables versus algorithms.
Journal of the American College of Cardiology.
57(5):612-8
[DOI] 10.1016/j.jacc.2010.08.643.
[PMID] 21272753.
2011
Genome Sequences of Mycoplasma Alligatoris A21Jp2(T) and Mycoplasma Crocodyli Mp145(T)
Journal of bacteriology.
193(11):2892-2893
[DOI] 10.1128/JB.00309-11.
[PMID] 21460083.
2011
Heart Failure Pharmacogenetics: Past, Present and Future
.
13:175-184
2011
Heart failure pharmacogenetics: past, present, and future.
Current cardiology reports.
13(3):175-84
[DOI] 10.1007/s11886-011-0181-6.
[PMID] 21416259.
2011
Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study.
Pharmacogenetics and genomics.
21(6):333-40
[DOI] 10.1097/FPC.0b013e3283452fec.
[PMID] 21562465.
2011
Meta-Analysis of Dense Gene-Centric Association Studies Reveals Common and Uncommon Variants Associated with Height
.
88:6-18
2011
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height.
American journal of human genetics.
88(1):6-18
[DOI] 10.1016/j.ajhg.2010.11.007.
[PMID] 21194676.
2011
Pharmacogenomics: Application to the Management of Cardiovascular Disease
Clinical Pharmacology & Therapeutics.
90:519-531
2011
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients.
Pharmacogenetics and genomics.
21(1):42-9
[DOI] 10.1097/FPC.0b013e328341e911.
[PMID] 21127457.
2011
Response To Letter Regarding Article “Chromosome 9P21 Haplotypes and Prognosis in White and Black Patients With Coronary Artery Disease”
Circulation-Cardiovascular Genetics.
4(4)
[DOI] 10.1161/CIRCGENETICS.111.960807.
2011
University of Florida Clinical and Translational Science Institute: transformation and translation in personalized medicine.
Clinical and translational science.
4(6):400-2
[DOI] 10.1111/j.1752-8062.2011.00348.x.
[PMID] 22212220.
2010
Aromatase gene polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner.
PloS one.
5(12)
[DOI] 10.1371/journal.pone.0015180.
[PMID] 21170323.
2010
Association Between Melatonin Receptor 1B Single Nucleotide Polymorphisms (Snps) and Response To Antihypertensive Drugs.
Clinical Pharmacology & Therapeutics.
87
2010
Atenolol exposure and risk for development of adverse metabolic effects: a pilot study.
Pharmacotherapy.
30(9):872-8
[DOI] 10.1592/phco.30.9.872.
[PMID] 20795842.
2010
Beta-blocker pharmacogenetics in heart failure.
Heart failure reviews.
15(3):187-96
[DOI] 10.1007/s10741-008-9094-x.
[PMID] 18437562.
2010
Combination antihypertensive treatment: is initiation order important?
Journal of clinical hypertension (Greenwich, Conn.).
12(8):565-7
[DOI] 10.1111/j.1751-7176.2010.00319.x.
[PMID] 20695931.
2010
Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide.
Journal of clinical hypertension (Greenwich, Conn.).
12(1):14-21
[DOI] 10.1111/j.1751-7176.2009.00185.x.
[PMID] 20047624.
2010
Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans
Clinical Pharmacology & Therapeutics.
87(4):459-464
[DOI] 10.1038/clpt.2009.223.
[PMID] 20072124.
2010
Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES).
Circulation. Cardiovascular genetics.
3(6):548-55
[DOI] 10.1161/CIRCGENETICS.110.957654.
[PMID] 21156931.
2010
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
Hypertension (Dallas, Tex. : 1979).
55(1):61-8
[DOI] 10.1161/HYPERTENSIONAHA.109.139592.
[PMID] 19917874.
2010
Lack of Association Between Polymorphisms in STK39, a Putative Thiazide Response Gene, and Blood Pressure Response to Hydrochlorothiazide
.
20:516-519
2010
Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide.
Pharmacogenetics and genomics.
20(8):516-9
[DOI] 10.1097/FPC.0b013e32833b5958.
[PMID] 20555294.
2010
Pharmacogenomics of antihypertensive drugs: past, present and future.
Pharmacogenomics.
11(4):487-91
[DOI] 10.2217/pgs.10.34.
[PMID] 20350127.
2010
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.
American journal of hypertension.
23(9):1014-22
[DOI] 10.1038/ajh.2010.98.
[PMID] 20725057.
2010
Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.
Trials.
11
[DOI] 10.1186/1745-6215-11-108.
[PMID] 21083927.
2010
Study of Vkorc1, Cyp2C9, and Cyp4F2 Polymorphisms and Their Association With Warfarin Dose Requirements in Egyptian Patients.
.
50
2010
Very important pharmacogene summary ADRB2.
Pharmacogenetics and genomics.
20(1):64-9
[DOI] 10.1097/FPC.0b013e328333dae6.
[PMID] 19927042.
2010
Very important pharmacogene summary: thiopurine S-methyltransferase.
Pharmacogenetics and genomics.
20(6):401-5
[DOI] 10.1097/FPC.0b013e3283352860.
[PMID] 20154640.
2010
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
Blood.
115(18):3827-34
[DOI] 10.1182/blood-2009-12-255992.
[PMID] 20203262.
2009
Altered beta-2 adrenergic receptor gene expression in human clinical hypertension.
Biological research for nursing.
11(1):17-26
[DOI] 10.1177/1099800409332538.
[PMID] 19254913.
2009
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.
Circulation. Cardiovascular genetics.
2(4):362-70
[DOI] 10.1161/CIRCGENETICS.109.857839.
[PMID] 20031608.
2009
Chromosome 7 and 19 trisomy in cultured human neural progenitor cells.
PloS one.
4(10)
[DOI] 10.1371/journal.pone.0007630.
[PMID] 19898616.
2009
Cxcl5/Ena-78 Genotype and Progression To Death Or Transplantation in Heart Failure Patients.
Clinical Pharmacology & Therapeutics.
85:S4-S5
2009
Data Trends and Results From An Hlb Testing Laboratory That Has Processed Over 64,000 Commercial and Research Samples Over a Two Year Period in Florida
Phytopathology.
99
2009
Estimation of the Warfarin Dose With Clinical and Pharmacogenetic Data
New England Journal of Medicine.
360:753-764
2009
Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension.
American journal of hypertension.
22(7):748-53
[DOI] 10.1038/ajh.2009.81.
[PMID] 19407804.
2009
Genotyping the GGGCGG tandem repeat promoter polymorphism in the 5-lipoxygenase enzyme gene (ALOX5) by pyrosequencing assay.
Genetic testing and molecular biomarkers.
13(3):361-5
[DOI] 10.1089/gtmb.2008.0103.
[PMID] 19473080.
2009
Hydrochlorothiazide and Atenolol Combination Antihypertensive Therapy: Effects of Drug Initiation Order
Clinical Pharmacology & Therapeutics.
86(5):533-539
[DOI] 10.1038/clpt.2009.101.
[PMID] 19571804.
2009
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study
Pharmacotherapy.
[DOI] 10.1592/phco.29.10.1157.
[PMID] 19792989.
2009
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
Pharmacotherapy.
29(10):1157-65
[DOI] 10.1592/phco.29.10.1157.
[PMID] 19792989.
2009
Long-Term Mortality Associated With New Onset Diabetes in Hypertensive Cad Patients Following Exposure To Antihypertensive Medications: Findings From the International Verapamail Sr-Trandolapril Study (Invest)
Journal of the American College of Cardiology.
53
2009
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.
American heart journal.
157(3):442-9
[DOI] 10.1016/j.ahj.2008.11.018.
[PMID] 19249413.
2009
Promoter Polymorphisms in Ace (Angiotensin I-Converting Enzyme) Associated With Clinical Outcomes in Hypertension
Clinical Pharmacology & Therapeutics.
85(1):36-44
[DOI] 10.1038/clpt.2008.194.
[PMID] 18946466.
2009
Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril.
Biochemical pharmacology.
77(7):1266-72
[DOI] 10.1016/j.bcp.2008.12.017.
[PMID] 19185566.
2009
Systolic blood pressure and subjective well-being in patients with coronary artery disease.
Clinical cardiology.
32(11):627-32
[DOI] 10.1002/clc.20501.
[PMID] 19711440.
2009
Very important pharmacogene summary: sulfotransferase 1A1.
Pharmacogenetics and genomics.
19(6):404-6
[DOI] 10.1097/FPC.0b013e32832e042e.
[PMID] 19451861.
2009
Warfarin Pharmacogenetics Reply
New England Journal of Medicine.
360
2008
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.
Blood.
112(4):1022-7
[DOI] 10.1182/blood-2008-01-134247.
[PMID] 18535201.
2008
A Polymorphism in the Nppa Gene Associates With Asthma
Clinical and Experimental Allergy.
38(7):1117-1123
[DOI] 10.1111/j.1365-2222.2008.02955.x.
[PMID] 18294255.
2008
A summer research training program to foster PharmD students’ interest in research.
American journal of pharmaceutical education.
72(2)
[PMID] 18483591.
2008
Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation.
Journal of translational medicine.
6
[DOI] 10.1186/1479-5876-6-11.
[PMID] 18331634.
2008
Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES).
American heart journal.
156(2):397-404
[DOI] 10.1016/j.ahj.2008.03.007.
[PMID] 18657677.
2008
Association of beta1-adrenergic receptor genetic polymorphism with mental stress-induced myocardial ischemia in patients with coronary artery disease.
Archives of internal medicine.
168(7):763-70
[DOI] 10.1001/archinte.168.7.763.
[PMID] 18413560.
2008
B1-Adrenergic Receptor Polymorphism Predicts Mental Stress-Induced Myocardial Ischemia in Patients With Coronary Artery Disease
Journal of the American College of Cardiology.
51
2008
Beta-Adrenergic Receptor Gene Polymorphisms and Beta-Blocker Treatment Outcomes in Hypertension
Clinical Pharmacology & Therapeutics.
84(6):715-721
[DOI] 10.1038/clpt.2008.139.
[PMID] 18615004.
2008
Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography.
The pharmacogenomics journal.
8(6):408-15
[DOI] 10.1038/sj.tpj.6500490.
[PMID] 18253135.
2008
Creating and evaluating genetic tests predictive of drug response.
Nature reviews. Drug discovery.
7(7):568-74
[DOI] 10.1038/nrd2520.
[PMID] 18587383.
2008
CYP4F2 genetic variant alters required warfarin dose.
Blood.
111(8):4106-12
[DOI] 10.1182/blood-2007-11-122010.
[PMID] 18250228.
2008
Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics.
Circulation.
118(13):1383-93
[DOI] 10.1161/CIRCULATIONAHA.107.704023.
[PMID] 18809808.
2008
Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia.
Pharmacogenetics and genomics.
18(6):507-14
[DOI] 10.1097/FPC.0b013e3282fc5801.
[PMID] 18496130.
2008
Protocols for cytogenetic studies of human embryonic stem cells.
Methods (San Diego, Calif.).
45(2):133-41
[DOI] 10.1016/j.ymeth.2008.03.005.
[PMID] 18593610.
2008
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.
Blood.
112(4):1013-21
[DOI] 10.1182/blood-2008-03-144899.
[PMID] 18523153.
2008
Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
871(1):130-4
[DOI] 10.1016/j.jchromb.2008.06.050.
[PMID] 18639501.
2008
Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis.
American journal of human genetics.
82(6):1241-8
[DOI] 10.1016/j.ajhg.2008.04.015.
[PMID] 18485328.
2008
Use of Pharmacogenetic and Clinical Factors To Predict the Therapeutic Dose of Warfarin
Clinical Pharmacology & Therapeutics.
84(3):326-331
[DOI] 10.1038/clpt.2008.10.
[PMID] 18305455.
2008
Vkorc1 and Cyp2C9 Polymorphisms Are Associated With Warfarin Dose Requirements in Turkish Patients
European journal of clinical pharmacology.
64(9):889-894
[DOI] 10.1007/s00228-008-0507-5.
[PMID] 18542936.
2008
Warfarin: an old drug but still interesting.
Pharmacotherapy.
28(9):1081-3
[DOI] 10.1592/phco.28.9.1081.
[PMID] 18752378.
2007
Assessment of Human Serotonin 1A Receptor Polymorphisms and SSRI Responsiveness
.
11(3):155-160
2007
Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness.
Molecular diagnosis & therapy.
11(3):155-60
[PMID] 17570737.
2007
Association of CYP3A5 Polymorphisms with Hypertension and Antihypertensive Response to Verapamil
Clinical Pharmacology & Therapeutics.
81(3):386-391
2007
Association of Diurnal Blood Pressure Pattern with Risk for Hospitalization or Death in Men with Heart Failure
.
13(8):656-662
2007
Association of diurnal blood pressure pattern with risk of hospitalization or death in men with heart failure.
Journal of cardiac failure.
13(8):656-62
[PMID] 17923358.
2007
Cytochrome P4502D6 (CYP2D6) Gene Locus Heterogeneity: Characterization of Gene Duplication Events
Clinical Pharmacology & Therapeutics.
81(2):242-251
2007
Epistatic Control of Human Obesity as Revealed by Linkage Disequilibrium Mapping: a Report from the NHLBI-Sponsored WISE Study
.
7:463-468
2007
Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study).
The American journal of cardiology.
99(11):1549-54
[PMID] 17531579.
2007
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing.
Pharmacogenomics.
8(5)
[PMID] 17465717.
2007
KCNMB1 Genotype Influences Response to Verapamil SR and Adverse Outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST)
.
17(9):719-729
2007
KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST).
Pharmacogenetics and genomics.
17(9):719-29
[PMID] 17700361.
2007
Modeling sequence-sequence interactions for drug response.
Bioinformatics (Oxford, England).
23(10):1251-7
[PMID] 17392331.
2007
Modeling Sequence-Sequence Interactions of Drug Response
.
23(10):1251-1257
2007
Pharmacogenetics of beta-blockers.
Pharmacotherapy.
27(6):874-87
[PMID] 17542770.
2007
PharmGKB Submission Update: IX. ADRB1 Gene Summary
.
59(1):2-4
2007
PharmGKB submission update: IX. ADRB1 gene summary.
Pharmacological reviews.
59(1):2-4
[PMID] 17329544.
2007
Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure.
The American journal of cardiology.
99(2):250-5
[PMID] 17223428.
2007
Single Nucleotide Polymorphism Discovery and Haplotype Analysis of Ca2+ -Dependent K+ Channel Beta-1 Subunit
.
17(4):267-275
2007
Single nucleotide polymorphism discovery and haplotype analysis of Ca2+-dependent K+ channel beta-1 subunit.
Pharmacogenetics and genomics.
17(4):267-75
[PMID] 17496725.
2007
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
Pharmacogenetics and genomics.
17(4):277-82
[PMID] 17496726.
2007
Synergistic Polymorphisms of Beta1- and Alpha2c-Adrenergic Receptors and the Influence on Left Ventricular Ejection Fraction Response to Beta-Blocker Therapy in Heart Failure
.
17(4):277-282
2007
The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response
Clinical Pharmacology & Therapeutics.
81(3):328-345
2006
A Bivariate Functional Mapping Model for Identifying Haplotypes that Control Drug Response for Systolic and Diastolic Blood Pressures
Pacific Symposium on Biocomputing.
572-583
2006
Discordant beta-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension.
Pharmacotherapy.
26(9):1247-54
[PMID] 16945046.
2006
Genetic Determinants of -Blocker Response: Influence of Phenotype and Pharmacokinetics on Drug Target Pharmacogenetics
.
6:174-178
2006
Highly Variable mRNA Expression and Splicing of L-Type Voltage-Dependent Calcium Channel Alpha Subunit 1c (CACNA1C) in Human Heart Tissues
.
16(10):735-745
2006
Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues.
Pharmacogenetics and genomics.
16(10):735-45
[PMID] 17001293.
2006
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
Clinical pharmacology and therapeutics.
79(4):291-302
[PMID] 16580898.
2006
Pharmacogenetics of chronic cardiovascular drugs: applications and implications.
Expert opinion on pharmacotherapy.
7(11):1417-27
[PMID] 16859425.
2006
Pharmacogenomics: Challenges and Opportunities
.
145(10):749-757
2006
Pharmacogenomics: challenges and opportunities.
Annals of internal medicine.
145(10):749-57
[PMID] 17116919.
2006
Re: Meckley LM, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genom 2006; 16:139-147.
Pharmacogenetics and genomics.
16(8)
[PMID] 16847430.
2006
Sustained Restoration of Autonomic Balance with Long- but not Short-Acting Metoprolol in Patients with Heart Failure
.
12(3):171-176
2006
Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure.
Journal of cardiac failure.
12(3):171-6
[PMID] 16624680.
2005
A Pharmacodynamic Model of the Effects of Controlled-Onset Extended-Release Verapamil on 24 Hour Ambulatory Blood Pressure
.
43:187-194
2005
Association between beta-adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study
International Journal of Obesity.
29(8):746-754
[DOI] 10.1016/j.cancergencyto.2004.08.016.
[PMID] 15917856.
2005
beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
Clinical pharmacology and therapeutics.
77(3):127-37
[PMID] 15735607.
2005
Beta1-Adrenergic Receptor Polymorphisms and Left Ventricular Remodeling Changes in Response to Beta-Blocker Therapy
.
15(4):227-234
2005
Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy.
Pharmacogenetics and genomics.
15(4):227-34
[PMID] 15864115.
2005
Cardiovascular pharmacogenomics.
Experimental physiology.
90(3):283-9
[PMID] 15778411.
2005
Hypertension pharmacogenomics: current status and future directions.
Current opinion in molecular therapeutics.
7(3):218-25
[PMID] 15977418.
2005
Sequencing Drug Response with HapMap
.
5(3):149-156
2005
Use of pharmacogenetics in clinical medicine: hype or hope?
Personalized medicine.
2(4):279-282
[DOI] 10.2217/17410541.2.4.279.
[PMID] 29788574.
2004
A Statistical Model for Functional Mapping of Quantitative Trait Loci Regulating Drug Response
.
4:315-321
2004
Caution with 1-Adrenergic Receptor Genotyping
Clinical Pharmacology & Therapeutics.
76
2004
Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory.
Pharmacotherapy.
24(6):720-6
[PMID] 15222661.
2004
Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms
.
44(10):1085-1105
2004
Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.
Journal of clinical pharmacology.
44(10):1083-105
[PMID] 15342610.
2004
Influence of gender and race on hemodynamic response to dobutamine during dobutamine stress echocardiography.
The American journal of cardiology.
94(4):535-8
[PMID] 15325950.
2004
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Clinical pharmacology and therapeutics.
76(6):536-44
[PMID] 15592325.
2004
Sequencing complex diseases With HapMap.
Genetics.
168(1):503-11
[PMID] 15454560.
2003
A haplotype-based algorithm for multilocus linkage disequilibrium mapping of quantitative trait loci with epistasis.
Genetics.
163(4):1533-48
[PMID] 12702696.
2003
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.
Clinical pharmacology and therapeutics.
74(1):44-52
[PMID] 12844134.
2003
Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges.
Pharmacogenetics.
13(9):525-34
[PMID] 12972951.
2003
Pharmacogenetics: potential for individualized drug therapy through genetics.
Trends in genetics : TIG.
19(11):660-6
[PMID] 14585618.
2003
The evolving role of nesiritide in advanced or decompensated heart failure.
Pharmacotherapy.
23(10):1266-80
[PMID] 14594345.
2002
Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics.
Pharmaceutical research.
19(12):1779-87
[PMID] 12523655.
2002
Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies.
Pharmacotherapy.
22(8):954-60
[PMID] 12173798.
2002
Dobutamine pharmacodynamics during dobutamine stress echocardiography and the impact of beta-blocker withdrawal: a report from the Women’s Ischemic Syndrome Evaluation Study.
Pharmacotherapy.
22(8):939-46
[PMID] 12173796.
2002
Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity.
Trends in molecular medicine.
8(6):300-5
[PMID] 12067617.
2002
Pharmacogenetics of cardiovascular drugs.
Briefings in functional genomics & proteomics.
1(1):66-79
[PMID] 15251067.
2002
Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2(5):287-96
[PMID] 14727958.
2002
Pharmacogenomics: A Scientific Revolution in Pharmaceutical Sciences and Pharmacy Practice. Report of the 2001/02 Academic Affairs Committee
American Journal of Pharmaceutical Education.
66:12S-15S
2001
Determination of Human Beta2-Adrenoceptor Haplotypes by Denaturation Selective Amplification and Subtractive Genotyping
.
1(4):315-322
2001
Drug target pharmacogenomics: an overview.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.
1(4):271-81
[PMID] 12083959.
2001
Effects of beta1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia
American Journal of Cardiology.
88(9):1034-1037
[DOI] 10.1016/S0002-9149(01)01986-5.
[PMID] 11704005.
2001
INVEST Substudies: Design and Patient Characteristics
Clinical Cardiology.
24(11):9-11
2001
Pharmacogenomics: The Inherited Basis for Inter-Individual Differences in Drug Response
.
2:9-39
2001
The Effect of Gut Metabolism on Tacrolimus Bioavailability in Renal Transplant Recipients
.
71(9):1303-1307
2000
CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences.
Journal of Pharmacology and Experimental Therapeutics.
294(3):1099-105
[PMID] 10945865.
2000
Effects of COER-Verapamil on Circadian Pattern of Forearm Vascular Resistance and Blood Pressure
.
40(12):1480-1487
2000
Gender Differences in Labetalol Kinetics: Importance of Determining Stereoisomer Kinetics for Racemic Drugs
Pharmacotherapy.
20(6):622-628
2000
Importance of Beta2 Adrenergic Receptor Genotype, Gender and Race on Albuterol-Evoked Bronchodilation in Asthmatics
Pulmonary Pharmacology & Therapeutics.
13(3):127-134
2000
Predictability of the Effects of Race or Ethnicity on Pharmacokinetics of Drugs (Invited Review)
.
38(2):53-60
2000
Sequencing of Beta2-Adrenoceptor Gene PCR Products Using Taq BigDye Terminator Chemistry Results in Inaccurate Base-Calling
Biotechniques.
29(5):962-964
2000
Simple Method for Determination of Terbutaline Plasma Concentration by High Performance Liquid Chromatography
.
741(2):307-312
1999
Effects of Gender and Race on Albuterol Pharmacokinetics
Pharmacotherapy.
19(2):157-161
1999
Impact of Genetic Polymorphisms of the Beta2-Adrenergic Receptor on Albuterol Bronchodilator Pharmacodynamics
Clinical Pharmacology & Therapeutics.
65(5):519-525
1999
Intranasal DDAVP-Induced Increases in Plasma Von Willebrand Factor Alter the Pharmacokinetics of High-Purity Factor VIII Concentrates in Severe Hemophilia A Patients
.
5(2):88-95
1998
The Role of Endothelin-1 in Heart Failure and Hypertension
Pharmacotherapy.
18:706-719
1997
Differences Between Blacks and Whites in Plasma Protein Binding of Drugs
.
51:485-488
1997
Influence of Race or Ethnicity on Pharmacokinetics of Drugs
Journal of Pharmaceutical Sciences.
86(12):1328-1333
1996
Metoprolol Metabolism Via Cytochrome P450 2D6 in Ethnic Populations
.
24(3):350-355
1996
Racial Differences in Propranolol Enantiomer Kinetics Following Simultaneous IV and Oral Administration
British Journal of Clinical Pharmacology.
42(3):339-346
1995
Influence of Metabolites on Protein Binding of Verapamil Enantiomers
British Journal of Clinical Pharmacology.
39(5):536-538
1995
Lymphocyte Beta2-Receptor Activity, Metoprolol Kinetics and Response to Metoprolol in Hypertensive Black Men
Pharmacotherapy.
15(2):150-157
1995
Metoprolol Minimizes Nighttime Blood Pressure Dip in Hypertensive Black Males
American Journal of Hypertension.
8(3):254-259
1995
Racial Differences in Beta-Adrenoceptor-Mediated Responsiveness
Journal of Cardiovascular Pharmacology.
25(1):90-96
1995
Racial Differences in Sensitivity to the Negative Chronotropic Effects of Propranolol in Healthy Males
Clinical Pharmacology & Therapeutics.
57(6):678-683
1993
Differences in Apparent Sensitivities of Chronotropy and Inotropy to Propranolol
.
34:256-262
1993
Direct High Performance Liquid Chromatographic Determination in Urine of the Enantiomers of Propranolol and its Major Basic Metabolite 4-Hydroxypropranolol
Journal of Chromatography a.
612(2):215-221
1993
Racial Differences in Lymphocyte Beta-Receptor Sensitivity to Propranolol
Life Sciences.
53(4):297-304
1992
Racial Differences in Propranolol Pharmacokinetics
Clinical Pharmacology & Therapeutics.
51(5):495-500
1991
Diastolic Dysfunction in Congestive Heart Failure
.
10(11):850-861
1990
Comparison of Hypersensitivity to Adrenergic Stimulation After Abrupt Withdrawal of Propranolol and Nadolol: Influence of Half-Life Differences
.
120(3):572-579
1990
Comparison of Single Dose and Steady State Nadolol Plasma Concentrations
Pharmaceutical Research.
7(9):953-956
1990
Use of Beta-Adrenergic Blocking Agents in Congestive Heart Failure
.
9(11):853-863
1989
Biphasic Pattern of Hypersensitivity Following Acute Propranolol Withdrawal in Normal Subjects
Life Sciences.
45(17):1547-1551
1989
Drug- or Hormone-Induced Adaptation: Model of Adrenergic Hypersensitivity
Journal of Pharmacokinetics and Pharmacodynamics.
17(3):347-364
1987
Lovastatin: A New Cholesterol Lowering Agent
Pharmacotherapy.
7(6):198-210
1986
Dose- and Time-Dependent Binding and Kinetics of Pindolol in Patients with Congestive Heart Failure
.
26(4):253-257
1986
Management of Pediatric Patients with Bronchiolitis in the Emergency Department
.
8:18-21
1985
Management of Bronchiolitis
.
4(3):299-303
1985
Prophylactic Antibiotics in Plastic Surgery
.
7:29-30
Grants
Dec 2021
– Nov 2022
Impact of CYP2D6 genotypes and inhibitors on opioid therapy in patients with pain
Role: Other
Funding: AMER COL OF CLINICAL PHAR
Sep 2021
– Aug 2023
Warfarin Pharmacogenetics at UF Health
Role: Co-Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Jan 2020
– Dec 2021
Personalizing thiazide therapy through clinical and microRNA biomarkers of response to thiazides
Role: Other
Funding: AMER HEART ASSOCIATION
Sep 2018
ACTIVE
Sparking Advancements in Genomic Medicine?
Role: Project Manager
Funding: NATL INST OF HLTH NHGRI
Jan 2018
– Apr 2023
Training Program for Applied Research and Development in Genomic Medicine
Role: Principal Investigator
Funding: NATL INST OF HLTH NHGRI
Jul 2016
– Sep 2020
A stem cell tactic to promote personalized medicine
Role: Project Manager
Funding: NATL INST OF HLTH NIGMS
Jul 2016
– Jun 2018
A Stem Cell Tactic to Promote Personalized Medicine in Hypertension
Role: Faculty
Funding: AMER HEART ASSOCIATION
Oct 2015
– Mar 2019
OneFlorida Clinical Research Consortium Phase II
Role: Project Manager
Funding: PATIENT-CENTERED OUTCOMES RES INST
Jul 2014
– Dec 2015
Using Different OMICS for the Identification of Novel Biomarkers of Blood Pressure Response to Antihypertensive Drugs
Role: Principal Investigator
Funding: AMER HEART ASSOCIATION
Jun 2013
– Sep 2018
Genomic Medicine Implementation: The Personalized Medicine Program
Role: Principal Investigator
Funding: NATL INST OF HLTH NHGRI
Mar 2011
– Feb 2016
Secondary Prevention of Subcortical Stroke Prevention Genetics Substudy Timing
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Aug 2010
– Jul 2017
Pharmacogenomic Evaluation of Antihypertensive Responses.
Role: Principal Investigator
Funding: NATL INST OF HLTH NIGMS
Jul 2007
– Aug 2016
Clinical and Translational Science Institute
Role: Project Manager
Funding: UF RESEARCH FOU
Education
Postdoctoral Fellowship in Pharmacokinetics/Clinical Pharmacology
1987-1989
·
The Ohio State University
Pharm.D.
1987
·
The University of Texas at Austin and The University of Texas Health Science Center at San Antonio
B.S.
1985
·
The Ohio State University
Contact Details
Phones:
- Business:
- (352) 273-6309
Emails:
- Business:
- julie.johnson@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100484
GAINESVILLE FL 32610 - Business Street:
-
1225 CENTER DR
HPNP 4332
GAINESVILLE FL 326103007